Epirubicin
Multi-parametric MRI
Chinese Academy of SciencesDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Multi-parametric MRI cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Chinese Academy of Sciences | D |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →